[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 689
Citations 0
February 6, 2013

β-Blocker Use for Patients With or at Risk for Coronary Artery Disease

Author Affiliations

Letters Section Editor: Jody W. Zylke, MD, Senior Editor.

Author Affiliation: Department of Medicine, Baylor College of Medicine, Houston, Texas (cshang9@gmail.com).

JAMA. 2013;309(5):438. doi:10.1001/jama.2012.128869

To the Editor: It is unfortunate that the observational study on β-blocker use and clinical outcomes in stable outpatients did not distinguish different types of β-blockers.1 In a review of β-blockers for hypertension, three-quarters of participants in randomized controlled trials (RCTs) used atenolol.2 Atenolol has been shown repeatedly to be no better than placebo in improving clinical outcomes such as reduction of mortality and cardiovascular events in RCTs and meta-analyses.2,3